FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an antigen-binding molecule for antigen elimination from plasma, a method for reducing the total concentration of an antigen or concentration of a free antigen in plasma, a method for increasing the capability of an antigen-binding molecule of eliminating plasma antigens, a method for producing an antigen-binding molecule for reducing the total concentration of an antigen or concentration of a free antigen in plasma (options). In one of embodiment, the antigen-binding molecule contains an antigen-binding domain, where the domain has antigen-binding activity that changes depending on pH, where a value of KD (pH 5.8) / KD (pH 7.4) equal to 2 or more is a KD ratio for an antigen in conditions of a range of acidic pH values to KD in conditions of a range of neutral pH values.
EFFECT: invention expands the arsenal of means for antigen elimination from plasma.
28 cl, 81 dwg, 54 tbl, 52 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGEN-BINDING MOLECULE TO ACCELERATE ANTIGEN DISAPPEARANCE THROUGH FcγRIIB | 2013 |
|
RU2812226C1 |
| ANTIGEN-BINDING MOLECULE TO ACCELERATE ANTIGEN DISAPPEARANCE THROUGH FCΓRIIB | 2013 |
|
RU2736349C2 |
| Fc-REGION OPTION | 2014 |
|
RU2757124C2 |
| VERSIONS OF FCΓRIIB-SPECIFIC FC-REGION | 2013 |
|
RU2729831C2 |
| METHOD OF PRODUCING VARIANTS OF FCYRIIB-SPECIFIC FC-REGION | 2013 |
|
RU2820161C1 |
| CARRIER CONTAINING A DRUG INTO A CELL FOR FORMING AN IMMUNE COMPLEX | 2012 |
|
RU2739792C1 |
| ANTIGEN-BINDING MOLECULE INDUCING AN IMMUNE RESPONSE TO A TARGET ANTIGEN | 2012 |
|
RU2722829C2 |
| ANTIGEN-BINDING MOLECULE SPECIFIC TO TARGET TISSUE | 2013 |
|
RU2743463C2 |
| POLYPEPTIDE VARIANT THAT HAS PRESERVED OR DECREASED BINDING ACTIVITY TO FcγRIIa, PHARMACEUTICAL COMPOSITION CONTAINING IT AND THEIR APPLICATION | 2012 |
|
RU2749357C2 |
| ANTIBODIES WITH MODIFIED AFFINITY TO FcRn, WHICH INCREASE ANTIGEN CLEARANCE | 2011 |
|
RU2810471C1 |
